Drug-Induced Liver Injury Clinical Trial
Official title:
Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population
Moxifloxacin is a broad-spectrum antibacterial agent used to treat common community-acquired
respiratory tract infections, complicated intra-abdominal infections, and pelvic
inflammatory disease. In the clinical development program, moxifloxacin was associated with
some hepatic adverse drug reactions. To evaluate further the hepatic safety profile of
moxifloxacin, a retrospective cohort study with nested case-control analysis will be
conducted to assess the rate of noninfectious acute liver injury among new users of
moxifloxacin and of other antimicrobials prescribed for similar indications, including
amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline,
levofloxacin, and telithromycin.
The study will be implemented in the population included in the HealthCore Integrated
Research Database (HIRD). Eligible patients are adults aged 18 years and older with
continuous enrollment in the HIRD for at least 6 months before their first claim for a
prescription for a study antimicrobial. Follow-up will start at the date of the first
prescription until the date of the earliest of the following events: noninfectious acute
liver injury, occurrence of an exclusion criterion, end of study period, disenrollment from
database, or death. Patients with chronic alcoholism or cirrhosis, infectious hepatitis,
HIV/AIDS, or pregnant women will not be included.
Study design is called 'Cohort study with nested case-control analysis" ;
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05517668 -
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
|
Phase 2 | |
Recruiting |
NCT05060289 -
A Prognostic Model for Drug-induced Liver Injury in China
|
||
Completed |
NCT03092817 -
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
|
Phase 3 | |
Completed |
NCT03211208 -
Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
|
||
Completed |
NCT02182167 -
A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02061826 -
Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)
|
N/A | |
Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A | |
Not yet recruiting |
NCT03091218 -
Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule.
|
N/A | |
Not yet recruiting |
NCT03091608 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule
|
N/A | |
Not yet recruiting |
NCT03091556 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill.
|
N/A | |
Not yet recruiting |
NCT03060252 -
Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill
|
N/A | |
Not yet recruiting |
NCT03091244 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule.
|
N/A | |
Completed |
NCT02407964 -
A Retrospective Study on Drug Induced Liver Injury in China
|
N/A | |
Active, not recruiting |
NCT05144217 -
Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
|
Phase 2/Phase 3 | |
Completed |
NCT01705041 -
Preliminary Evaluation of a Point-Of-Care Liver Function Test
|
N/A | |
Recruiting |
NCT02086708 -
Ultrasound Method to Measure Fibrosis of the Liver in Children
|
N/A | |
Recruiting |
NCT05465642 -
Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
|
||
Completed |
NCT05532345 -
Discrimination of DILI and AIH by Artificial Intelligence
|
||
Completed |
NCT03602703 -
Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
|
||
Active, not recruiting |
NCT03100786 -
Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis
|
Phase 3 |